Multi-color Mapping of Cancer Molecular Signatures and Tumor microenvironment

癌症分子特征和肿瘤微环境的多色绘图

• 批准号: 10169065
• 负责人: Jenny J. Yang
• 金额: $ 8.09万
• 依托单位: GEORGIA STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-18 至 2022-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10169065
• 关键词: 2019-nCoV; Acute; Address; Advanced Development; Animal Model; Atlas of Cancer Mortality in the United States; Binding; Biological Markers; Biology; Biopsy; COVID-19; Cancer Patient; China; Chronic; Clinical; Collagen; Color; Contrast Media; Coronavirus Infections; Data; Detection; Development; Diagnosis; Diagnostic; Diagnostic Imaging; Disease; Disease Outbreaks; Disease Progression; Early Diagnosis; Exhibits; Fibrosis; Funding; Future; Goals; Heart; High Resolution Computed Tomography; Hospitals; Image; Impairment; Infection; Injury; Ionizing radiation; Lung; Lung Neoplasms; Lung diseases; Lung infections; Magnetic Resonance Imaging; Malignant Neoplasms; Malignant neoplasm of lung; Medical; Metals; Metastatic Neoplasm to the Lung; Methodology; Molecular; Mus; Names; Neoplasm Metastasis; Non-Invasive Cancer Detection; Organ; Oxygen; Patients; Pattern; Penetration; Pharmaceutical Preparations; Pneumonia; Property; Proteins; Pulmonary Fibrosis; Radiation Tolerance; Radiologic Finding; Relaxation; Resolution; SARS coronavirus; Sampling Errors; Satellite Viruses; Sensitivity and Specificity; Severe Acute Respiratory Syndrome; Specificity; Staging; Symptoms; Thoracic Radiography; Tissues; Tumor stage; Validation; Viral; Virus; Virus Diseases; Virus-like particle; X-Ray Computed Tomography; base; cancer heterogeneity; chest computed tomography; density; design; effective therapy; high risk; imaging capabilities; imaging modality; imaging platform; improved; in vivo; in vivo imaging; lung imaging; molecular marker; mouse model; non-invasive imaging; novel; novel coronavirus; pandemic disease; patient stratification; prevent; quantitative imaging; respiratory; response; targeted treatment; treatment strategy; tumor microenvironment; tumor molecular fingerprint; viral detection; viral transmission

Abstract Since the recent identification of a novel coronavirus from the pneumonia outbreak in Wuhan, China, now named as SARS-CoV-2, the virus has spread globally very rapidly. SARS-CoV-2 is closely related to SARS-CoV emerged in 2003. While there are many factors associated the virus transmission, the pattern of SARS-CoV-2 spread is distinctly different from that of SARS-CoV. Evidence shows that there is virus transmission before onset of symptoms in patients. Diagnosis of the virus infection is more difficult because the infection of SARS- CoV-2 may be in the lower respiratory track. This proposal takes advantage of our pioneered imaging platform and protein agents to rapid develop pMRI diagnostic imaging with strong translational potential in facilitating effective treatment to halt further chronic and pandemic lung disease progression. It is highly transformative and specifically address the call of proposal for Urgent Supplement using existing imaging modality and MRI and largely extended its capability. The developed MRI diagnostic imaging with its high resolution, non-radiative, and much improved sensitivity than current CT in clinical will significantly facilitate accurate detection of coronavirus infection in patient and control of Covid-19 and other SARS-like COV infections.

抽象的 自最近从中国武汉肺炎爆发中鉴定出一种新颖的冠状病毒 作为SARS-COV-2，该病毒在全球范围内迅速传播。 SARS-COV-2与SARS-COV密切相关 在2003年出现。尽管病毒传播有许多因素，但SARS-COV-2的模式 传播与SARS-COV明显不同。有证据表明之前有病毒传播 患者症状的发作。病毒感染的诊断更加困难，因为SARS的感染 COV-2可能在下呼吸道中。该建议利用了我们开创性的成像平台 和蛋白质剂以快速发展PMRI诊断成像，具有强大的转化潜力 有效的治疗方法可以停止进一步的慢性和大流行肺部疾病进展。它是高度变革性的， 专门针对使用现有成像方式和MRI的提案提案的呼吁，以及 很大程度上扩展了其能力。开发的MRI诊断成像具有高分辨率，非辐射性和 在临床中，比电流CT的灵敏度大大提高将显着促进冠状病毒的准确检测 患者的感染和对COVID-19和其他类似SARS的COV感染的控制。